SPONTAN was administered to the initial patient Under the authorized prescriber scheme

LTR Pharma Limited (ASX: LTP) has announced a significant advancement in the rollout of its erectile dysfunction treatment, SPONTAN, now prescribed to first patients under the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme (APS). This scheme marks a critical development in SPONTAN's market introduction strategy by enabling faster access for a broader range of patients with erectile dysfunction rather than on a case-by-case basis, as previously done under the Special Access Scheme. The involvement of specialists, such as Professor Eric Chung, an expert in urology and men's health, highlights SPONTAN's potential to meet previously unmet needs in this area. The APS aims to improve treatment outcomes through the expertise of experienced practitioners.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com